| Clinical, prognostic, and therapeutic aspects of urachal carcinoma—a comprehensive review with meta-analysis of 1,010 cases T Szarvas, O Módos, C Niedworok, H Reis, A Szendröi, MA Szász, ... Urologic Oncology: Seminars and Original Investigations 34 (9), 388-398, 2016 | 166 | 2016 |
| Biomarkers in urachal cancer and adenocarcinomas in the bladder: a comprehensive review supplemented by own data H Reis, U Krafft, C Niedworok, O Módos, T Herold, M Behrendt, ... Disease markers 2018, 2018 | 57 | 2018 |
| Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: occurence and prognostic significance O Módos, H Reis, C Niedworok, H Rübben, A Szendröi, J Tímár, K Baghy, ... Oncotarget 7 (26), 39293, 2016 | 51 | 2016 |
| P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas H Reis, KE van der Vos, C Niedworok, T Herold, O Módos, A Szendrői, ... International Journal of Cancer 143 (7), 1764-1773, 2018 | 50 | 2018 |
| Urachal carcinoma of the bladder: impact of clinical and immunohistochemical parameters on prognosis C Niedworok, M Panitz, T Szarvas, H Reis, AC Reis, A Szendröi, ... The Journal of Urology 195 (6), 1690-1696, 2016 | 42 | 2016 |
| Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer T Szarvas, S Sevcenco, O Módos, D Keresztes, P Nyirády, A Kubik, ... Urologic Oncology: Seminars and Original Investigations 36 (6), 312. e9-312. e15, 2018 | 32 | 2018 |
| Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer U Krafft, S Tschirdewahn, J Hess, NN Harke, B Hadaschik, C Olah, ... Urologic Oncology: Seminars and Original Investigations 37 (11), 810. e7-810 …, 2019 | 29 | 2019 |
| Why are upper tract urothelial carcinoma two different diseases? T Szarvas, O Módos, A Horváth, P Nyirády Translational Andrology and Urology 5 (5), 636, 2016 | 28 | 2016 |
| High serum PD-L1 levels are associated with poor survival in urothelial cancer patients treated with chemotherapy and immune checkpoint inhibitor therapy U Krafft, C Olah, H Reis, C Kesch, C Darr, V Grünwald, S Tschirdewahn, ... Cancers 13 (11), 2548, 2021 | 19 | 2021 |
| STIP1 tissue expression is associated with survival in chemotherapy-treated bladder cancer patients U Krafft, S Tschirdewahn, J Hess, NN Harke, BA Hadaschik, P Nyirády, ... Pathology & Oncology Research 26, 1243-1249, 2020 | 16 | 2020 |
| Prevalence of APC and PTEN Alterations in Urachal Cancer N Nagy, H Reis, B Hadaschik, C Niedworok, O Módos, A Szendrői, K Bíró, ... Pathology & Oncology Research 26, 2773-2781, 2020 | 12 | 2020 |
| Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration‐resistant prostate cancer T Szarvas, S Sevcenco, O Modos, D Keresztes, P Nyirady, A Csizmarik, ... BJU international 122 (4), 695-704, 2018 | 10 | 2018 |
| Soluble syndecan-1 levels are associated with survival in platinum-treated bladder cancer patients C Olah, S Tschirdewahn, MJ Hoffmann, U Krafft, B Hadaschik, P Nyirady, ... Diagnostics 10 (11), 864, 2020 | 7 | 2020 |
| Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas M Varadi, N Nagy, H Reis, B Hadaschik, C Niedworok, O Modos, ... Cancer medicine 12 (7), 9041-9054, 2023 | 6 | 2023 |
| Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer D Keresztes, A Csizmarik, N Nagy, O Módos, T Fazekas, T Bracht, B Sitek, ... Journal of Cellular and Molecular Medicine 26 (4), 1332-1337, 2022 | 4 | 2022 |
| Mutation analysis of EGFR signal transduction pathway in urachal carcinoma O Modos, T Szarvas, H Reis, C Niedworok, H Rübben, A Szendröi, ... European Urology Supplements 6 (14), e1215, 2015 | 3 | 2015 |
| Comparative proteome analysis identified NAMPT as a potential serum marker for the prediction of docetaxel-resistance in prostate cancer D Keresztes, O Módos, M Szűcs, A Hüttl, A Csizmarik, N Nagy, V Kretz, ... European Urology Supplements 18 (1), e482, 2019 | 2 | 2019 |
| Characteristics of bladder recurrence after radical nephroureterectomy in upper urinary tract cancer PT Kovács, D Juhász, O Módos, I Kocsmár, A Terebessy, G Lotz, ... Orvosi Hetilap 161 (21), 881-888, 2020 | 1 | 2020 |
| Next-generation sequencing-based molecular analysis of urachal adenocarcinomas N Nagy, A Kubik, A Szendrői, O Módos, A Csizmarik, C Oláh, D Keresztes, ... European Urology Supplements 18 (2), e2408, 2019 | 1 | 2019 |
| MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer T Szarvas, S Sevcenco, O Módos, D Keresztes, P Nyirády, A Csizmarik, ... | 1 | 2018 |
